Trial Profile
Open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BASALT-1
- Sponsors Novartis
- 27 Jun 2019 Trial has been completed in Hungary, according to European Clinical Trials Database record.
- 26 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 26 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov record.